Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
about
Structural Insights into Binding of the Antifungal Drug Fluconazole to Saccharomyces cerevisiae Lanosterol 14α-Demethylase.Clinical characteristics and outcomes in 303 HIV-infected patients with invasive fungal infections: data from the Prospective Antifungal Therapy Alliance registry, a multicenter, observational studyEpidemiology and outcomes of invasive candidiasis due to non-albicans species of Candida in 2,496 patients: data from the Prospective Antifungal Therapy (PATH) registry 2004-2008.Accumulated safety data of micafungin in therapy and prophylaxis in fungal diseases.Population-based analysis of invasive fungal infections, France, 2001-2010.Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital.Post-transcriptional regulation of the Sef1 transcription factor controls the virulence of Candida albicans in its mammalian hostCandidemia in the critically ill: initial therapy and outcome in mechanically ventilated patientsDonor transmission of Cryptococcus neoformans presenting late after renal transplantationDetermination of antifungal susceptibility patterns among the clinical isolates of Candida speciesAnidulafungin compared with fluconazole in severely ill patients with candidemia and other forms of invasive candidiasis: support for the 2009 IDSA treatment guidelines for candidiasisMicrobiological profile of organisms causing bloodstream infection in critically ill patientsTreatment of candidemia and invasive candidiasis in the intensive care unit: post hoc analysis of a randomized, controlled trial comparing micafungin and liposomal amphotericin B.The Prospective Antifungal Therapy Alliance(®) registry: A two-centre Canadian experience.Emerging moulds: epidemiological trends and antifungal resistance.Diagnosing invasive fungal disease in critically ill patients.Treatment and outcomes of Candida osteomyelitis: review of 53 cases from the PATH Alliance® registry.Treatment and outcomes of invasive fusariosis: review of 65 cases from the PATH Alliance(®) registry.Current recommendations and importance of antifungal stewardship for the management of invasive candidiasis.Synergistic effects of amiodarone and fluconazole on Candida tropicalis resistant to fluconazole.A Risk Score for Fluconazole Failure among Patients with Candidemia.Epidemiological features of invasive mold infections among solid organ transplant recipients: PATH Alliance® registry analysis.Prospective antifungal therapy (PATH) alliance(®) : focus on mucormycosis.Outbreak of invasive aspergillosis after major heart surgery caused by spores in the air of the intensive care unit.Resource utilization and cost of treatment with anidulafungin or fluconazole for candidaemia and other forms of invasive candidiasis: focus on critically ill patients.Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry.Natural Killer Cells in Antifungal Immunity.Impact of Homologous Resistance Mutations from Pathogenic Yeast on Saccharomyces cerevisiae Lanosterol 14α-Demethylase.
P2860
Q27324352-55C08170-F36D-4204-8DFE-022362311064Q30781344-26963CC6-A54C-4B4E-B34E-7AC147FF6D53Q30834974-30BBF4FB-7A45-4935-95A0-85E5BEF43CCDQ33816237-AF4BE002-D512-4896-8F3B-A11B94F24618Q33816423-D8FE4B8E-50F9-4B06-99E2-A7128E11C82FQ34221581-6671C1F2-8385-4EFE-9476-B8657777760CQ34468966-B3BBF017-F961-4DA6-8DB2-5A2EAEE176B0Q35028914-8EBC65A4-4D53-41D4-9D9C-D20DDB9C971CQ35608463-16E12043-461E-482F-BBA0-BA5B7D0F5439Q35646997-70601FEA-6E87-4274-B686-629FBD778A88Q35908313-27340840-848A-41E4-B13C-282B75AC46B6Q36442068-B08B10D7-A9F3-4A8D-870E-C18FEA620A60Q37443139-4D53F199-6408-4750-9047-A77FEE94E68FQ37632406-1D39CE8D-A4F6-4373-9BFD-945D6493BB43Q37889387-397679CE-47DD-4EC6-B3CB-E2C3E218DDEDQ37900310-648B2877-F345-49E2-AEEB-EAFEFCF0804DQ38125931-B49C29B5-70DC-49FE-BC79-F69EEF946651Q38221405-632956A3-B177-4281-96E5-79B4CC07AE04Q38531765-58B4A00E-6DFC-4808-9D7F-35B21F03A7B9Q39767106-FABE12C8-646E-4A98-ADAB-D479D313D923Q40306211-6741DCCF-3A37-4D82-A850-4DA665117296Q40517245-7E63CE07-E51A-4940-9E87-5A880B146494Q42243344-7896D243-5037-486C-A804-5F03348910CAQ44010583-A30483C0-B660-4FA8-8AD0-56BC6872A15CQ45892642-52F60AB3-8F67-41AB-A80E-E35A1E889462Q45938423-985FC502-567A-479A-B2A0-978CD84A8319Q46246454-687032AB-F62F-42B4-9C15-BB59E8078A7EQ51771420-76B505BD-78C2-4961-A8FD-A191B377C64D
P2860
Presentation of the PATH Alliance registry for prospective data collection and analysis of the epidemiology, therapy, and outcomes of invasive fungal infections.
description
2007 nî lūn-bûn
@nan
2007 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
Presentation of the PATH Allia ...... of invasive fungal infections.
@ast
Presentation of the PATH Allia ...... of invasive fungal infections.
@en
type
label
Presentation of the PATH Allia ...... of invasive fungal infections.
@ast
Presentation of the PATH Allia ...... of invasive fungal infections.
@en
prefLabel
Presentation of the PATH Allia ...... of invasive fungal infections.
@ast
Presentation of the PATH Allia ...... of invasive fungal infections.
@en
P2093
P1476
Presentation of the PATH Allia ...... of invasive fungal infections.
@en
P2093
Ali J Olyaei
David L Horn
Dionissios Neofytos
Elias J Anaissie
Jay A Fishman
Karen M Webster
Kieren A Marr
Mark A Weiss
William J Steinbach
P304
P356
10.1016/J.DIAGMICROBIO.2007.06.008
P577
2007-09-20T00:00:00Z